Microsoft word - explanatory_note_ 2010_list_final_en_rev_web

September 19, 2009
2010 Prohibited List
Summary of Major Modifications


 The introductory sentence on the use of drugs limited to medically justified  The reference to Specified Substances has been amended in accordance with

S1: Anabolic Agents
 The International Nonproprietary Name (INN) for methyltrienolone has been  Comment S1.1b, including revisions, is addressed in another WADA document S2. Peptide Hormones, Growth Factors and Related Substances  In order to better define the substances within this category, the title has been revised to “Peptide Hormones, Growth Factors and Related Substances”.  To reflect the growing number of new erythropoeisis-stimulating substances available, methoxy polyethylene glycol-epoetin beta (CERA) has been added as  The issue of growth factors enhancing certain functions was addressed in more detail. Additional examples of growth factors affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching [e.g. Platelet-derived Growth Factor (PDGF), Fibroblast Growth Factors (FGFs), Vascular-Endothelial Growth Factor (VEGF), Hepatocyte Growth Factor (HGF)] were included.  The status of Platelet-derived preparations (e.g. Platelet Rich Plasma, “blood  Comment S2 is addressed in another WADA document (Technical Document  The use of salbutamol and salmeterol by inhalation no longer requires a TUE but  It is specified that the maximum dose for the controlled pharmacokinetic study cannot exceed the maximum therapeutic dose for inhaled salbutamol (1600 µg/day).  Two examples of aromatase inhibitors, androstene-3,6,17 trione (6-oxo) and androsta-1,4,6-triene-3,17-dione (androstatrienedione) have been added in view of their wide availability as components of nutritional supplements.  The status of glycerol (oral and intravenous) as a plasma expander was clarified  The non-prohibited status of pamabrom was clarified because it is a weak diuretic largely available as a combined over-the-counter medication for pre-menstrual/menstrual symptoms.

M1. Enhancement of Oxygen Transfer
 Supplemental oxygen is no longer prohibited.  Proteases have been added as an example of sample adulteration.  The status of intravenous infusions has been reviewed and now reads: “Intravenous infusions are prohibited except for those legitimately received in the course of hospital admissions or clinical investigations.”  For clarification purposes the gene doping definition was reworded and split into

S6. Stimulants
 Three stimulants, namely benfluorex, prenylamine, both known to metabolize to non-specified stimulants (amphetamine or norfenfluramine) as well as methylhexaneamine, a non-therapeutic substance, were added to the closed list of non-specified stimulants.  Until 2003, the stimulant pseudoephedrine had been prohibited in sports with a threshold of 25 μg/mL. Pseudoephedrine has been included in the Monitoring Program since 2004. Results from the Monitoring Program over the past 5 years have shown a sustained increase in urinary concentrations of pseudoephedrine. In addition, there is clear evidence of abuse in some sports and some regions which show clusters of samples with high pseudoephedrine concentrations many times in excess of concentrations normally found. Furthermore, the available literature demonstrates scientific proof of its performance enhancing effects at certain doses. Therefore, the List Committee has reintroduced pseudoephedrine as a specified stimulant in the 2010 Prohibited List at a urinary threshold of 150 µg/mL based on the results from controlled excretion studies as well as the literature. Given the wide availability of pseudoephedrine-containing medicines, WADA recommends that the reintroduction of pseudoephedrine is supported by active information/education campaign by all stakeholders.  Although pseudoephedrine is now prohibited, it will remain in the Monitoring Program for urinary concentrations below 150 µg/mL.  It is clarified that synthetic cannabinoids are covered by this section.


P1. Alcohol and P2. Beta-blockers
 As the responsibility for testing in the sports of Boules and Archery has been transferred from the International Paralympic Committee (IPC) to the World Bowling Federation and the International Archery Federation (FITA), respectively, references to the IPC have been deleted.


China pharma holdings, inc

China Pharma Holdings, Inc. Announces SFDA Approval For Production of Omeprazole Injections Broadens Product Offerings for Multiple Therapeutic Markets – HAIKOU CITY, China, August 18, 2009 - China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that


mediapis®.news :: 12/2012 vom 18. Dezember 2012 :: =========================================================== Die Themen und Links dieses Newsletters wurden sorgfältig recherchiert, geprüft sowie nach bestem Wissen und Gewissen ausgewählt. Unser Newsletter ist ausschließlich für den Empfänger (ab Januar 2013 - NUR für Mitglieder ) bestimmt und nicht zur Weit

Copyright ©2018 Sedative Dosing Pdf